Cargando…
Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder
Premenstrual dysphoric disorder (PMDD) is estimated to affect 3%–8% of reproductive age women. Multiple therapeutic modalities have been evaluated with varying efficacy for the associated somatic and mood symptoms. The majority of older studies had shown that oral contraceptive pills (OCs) were most...
Autores principales: | Breech, Lesley L, Braverman, Paula K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971718/ https://www.ncbi.nlm.nih.gov/pubmed/21072278 |
Ejemplares similares
-
Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol
por: De Berardis, Domenico, et al.
Publicado: (2007) -
Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne
por: Tan, Jerry KL, et al.
Publicado: (2010) -
Ultrasound-Assisted Extraction, Followed by Gas Chromatography–Mass Spectrometry for the Simultaneous Quantification of Ethinyl Estradiol and Drospirenone in Contraceptive Formulations
por: Peña, Javier, et al.
Publicado: (2023) -
Health Status Is Affected, and Phase I/II Biotransformation Activity Altered in Young Women Using Oral Contraceptives Containing Drospirenone/Ethinyl Estradiol
por: Venter, Gerda, et al.
Publicado: (2021) -
The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg
por: Krishnan, Sheila, et al.
Publicado: (2010)